Effects of perinatal exposure to flutamide on sex hormones and androgen-dependent organs in F1 male rats.
Flutamide, which has antiandrogenic properties, was administered to pregnant rats, and effects on male offspring were examined. Crj: CD (SD) IGS (SPF) females were administered flutamide (0.15, 0.6, 2.5, 10.0, 100 mg/kg, p.o.) from gestation Day 14 to post parturition Day 3. The number of pups, body weights, clinical features, anogenital distance (AGD), nipple retention, testicular descent, and urogenital malformation in F1 males were examined. Hormone measurement, necropsy and histopathological examination were carried out at post-neonatal Day 4 (PND 4) and PND 60. Sperm analysis was also carried out at PND 60. Decrease in body weight was seen in the 100 mg/kg group and the AGD was decreased at 2.5 mg/kg and above. Retention of nipples, hypospadia, vaginal pouches, penis malformation, unilateral ectopic testis, and decrease of organ weights (prostate, seminal vesicles, levator ani muscle plus bulbocavernosus muscle, testis) were observed at 10 mg/kg and above. Testicular testosterone (T) was increased significantly with 100 mg/kg at PND 4 and tendencies for increase were observed in serum T, LH and FSH at 10 mg/kg and more at the same time point. In contrast, elevated levels of LH and FSH were seen with 100 mg/kg at PND 60. Histopathological examination revealed defects or hypoplastic changes of genital organs (> or = 10 mg/kg), squamous metaplasia (10 mg/kg) or mucification (100 mg/kg) of the urethral diverticulum epithelium and inflammation of genital organs (100 mg/kg). Though only undescended testes lacked spermatogenesis at 10 mg/kg, atrophic change of seminiferous tubules and azoospermia were observed in the 100 mg/kg group, despite testicular descent. Perinatal administration of flutamide affected F1 male rats at 2.5 mg/kg and above. In addition to urogenital malformation, 100 mg/kg flutamide caused high LH and FSH levels at PND 60. This study indicates that the most sensitive parameter is AGD, whereby reduction was observed at 2.5 mg/kg. A clear no-effect level (NOEL: 0.6 mg/kg) was obtained in this perinatal study of an antiandrogenic chemical.
Miyata
Kaori
K
Environmental Health Science Lab., Sumitomo Chemical Co., Ltd., 3-1-98, Kasugade-naka, Konohana-ku, Osaka 554-8558, Japan.
Yabushita
Setsuko
S
Sukata
Tokuo
T
Sano
Masashi
M
Yoshino
Hiroko
H
Nakanishi
Takumi
T
Okuno
Yasuyoshi
Y
Matsuo
Masatoshi
M
D000014:Abnormalities, Drug-Induced; D000284:Administration, Oral; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D000831:Animals, Newborn; D004305:Dose-Response Relationship, Drug; D005260:Female; D005485:Flutamide / Q000008:administration & dosage / Q000633:toxicity*; D005837:Genitalia, Male / Q000002:abnormalities / Q000187:drug effects* / Q000473:pathology; D012739:Gonadal Steroid Hormones / Q000097:blood*; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains; D012741:Sexual Maturation / Q000187:drug effects; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D012739:Gonadal Steroid Hormones; D013739:Testosterone; D005485:Flutamide